Printer Friendly

ARTHROCARE GETS FDA CLEARANCE FOR ALL-PEEK IMPLANT SYSTEM.

ArthroCare Corp.(Nasdaq:ARTC), Austin, Texas, has received 510(k) clearance from the U.S. Food and Drug Administration to market its Magnum PI Knotless Implant System, which utilizes implants made of polyetheretherketone (PEEK) for the attachment of soft tissue to bone.

The Magnum PI Knotless Implant System provides surgeons who prefer non metallic anchors with a radiolucent elastic plastic (PEEK) anchor product line which utilizes the Opus platform's proven technology and operating principles.

"Receiving clearance from the FDA to market the Magnum PI is a great next step for our Opus collection of products," said Jack Giroux, president of ArthroCare Sports Medicine. "ArthroCare is providing clinically proven tools orthopedic surgeons need to achieve fast, simple solutions to challenging fixation problems in the shoulder and elsewhere. We've now expanded the range of surgical options to include non-metallic, PEEK anchors. It's something that many of the surgeons have been asking for, and it's great to be able to deliver such an exciting and innovative product."

Giroux also said that the Magnum PI Knotless Implant System can be used in shoulder-related procedures such as rotator cuff repairs and in Achilles tendon repair in the foot, among several other indications. He explained that ArthroCare's knotless implant systems are designed to enable trained physicians to perform such surgeries faster and easier.

About ArthroCare

Founded in 1993, ArthroCare Corp. is a highly innovative, multi-business medical device company that develops, manufactures and markets minimally invasive surgical products. With these products, ArthroCare targets a multi-billion dollar market opportunity across several medical specialties, significantly improving existing surgical procedures and enabling new, minimally invasive procedures. Many of ArthroCare's products are based on its patented Coblation technology, which uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue minimizing damage to healthy tissue. Used in more than four million surgeries worldwide,

Coblation-based devices have been developed and marketed for sports medicine; spine/neurologic; ear, nose and throat (ENT); cosmetic; urologic and gynecologic procedures. ArthroCare also has added a number of novel technologies to its portfolio, including Opus Medical sports medicine, Parallax spine and Applied Therapeutics ENT products, to complement Coblation within key indications.

For more information, call 310/937-2009 or visit http://www.arthrocare.com.
COPYRIGHT 2007 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Date:Jun 1, 2007
Words:369
Previous Article:HEMISPHERX/ARMADA TO LAUNCH ALFERON N INJECTION.
Next Article:AVICENA FILES COMPOSITION OF MATTER PATENT APPLICATION.
Topics:


Related Articles
BIOCOMPATIBLE THERMOPLASTIC SOLUTION FOR IN-VIVO APPLICATIONS.
ARTHROCARE'S COBLATION SYSTEM TO BE USED FOR BRAIN SURGERY.
ARTHROCARE GETS FDA CLEARANCE FOR NOVEL ENT DEVICE.
Synovis Life granted important FDA indication and United States patent for Veritas collagen matrix.
Specialized Medical Devices.
Specialized Medical Devices: www.specializedmedical.com.
FDA approves SBi's thumb implant.
Specialized Medical Devices, Inc.: www.specializedmedical.com.
FDA clears BioMedical Enterprises' spine device.
Specialized Medical Devices, Inc.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |